

1 **Estimating the effectiveness of shielding during pregnancy against SARS-CoV-2 in New**  
2 **York City during the first year of the COVID-19 pandemic**

3

4 Siyu Chen<sup>1\*</sup>, Elisabeth A Murphy<sup>2</sup>, Angeline G Pendergrass<sup>3</sup>, Ashley C Sukhu<sup>4</sup>, Dorothy  
5 Eng<sup>4</sup>, Magdalena Jurkiewicz<sup>4</sup>, Iman Mohammed<sup>5</sup>, Sophie Rand<sup>2</sup>, Lisa J White<sup>1</sup>, Nathaniel  
6 Hupert<sup>1,6,7</sup>, Yawei J Yang<sup>2,4\*</sup>

7

8 **Affiliations:**

9 <sup>1</sup> Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield  
10 Department of Medicine, University of Oxford, United Kingdom

11 <sup>2</sup> Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York,  
12 NY, USA

13 <sup>3</sup> Department of Earth and Atmospheric Sciences, Cornell University, Ithaca, NY, USA

14 <sup>4</sup> New York Presbyterian-Weill Cornell Medicine, New York, NY USA

15 <sup>5</sup> Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA

16 <sup>6</sup> Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA

17 <sup>7</sup> Department of Medicine, Weill Cornell Medicine, New York, NY, USA

18

19 **\*Co-Corresponding Authors:**

20 Siyu Chen and Yawei J Yang

21 Department of Pathology & Laboratory Medicine

22 1300 York Ave, F-701

23 New York, NY 10065

24 [yang@med.cornell.edu](mailto:yang@med.cornell.edu) and [siyu.chen@ndm.ox.ac.uk](mailto:siyu.chen@ndm.ox.ac.uk)

25

26 **Abstract**

27 Pregnant patients have increased morbidity and mortality in the setting of SARS-CoV-2  
28 infection. The exposure of pregnant patients in New York City to SARS-CoV-2 is not well  
29 understood due to early lack of access to testing and the presence of asymptomatic  
30 COVID-19 infections. Before the availability of vaccinations, preventative (shielding)  
31 measures, including but not limited to wearing a mask and quarantining at home to limit  
32 contact, were recommended for pregnant patients. Using universal testing data from  
33 2196 patients who gave birth from April through December 2020 from one institution in  
34 New York City, and in comparison, with infection data of the general population in New  
35 York City, we estimated the exposure and real-world effectiveness of shielding in  
36 pregnant patients. Our Bayesian model shows that patients already pregnant at the  
37 onset of the pandemic had a 50% decrease in exposure compared to those who became  
38 pregnant after the onset of the pandemic and to the general population.

39

40 **Introduction**

41 Pregnant patients make up a vulnerable patient population in any infectious disease  
42 outbreak. When New York City became the epicenter of COVID-19 pandemic in March  
43 2020, the impact of SARS-CoV-2 infection on pregnant patients and their neonates was  
44 not well understood<sup>1</sup>. In addition, the prevalence of the disease in the pregnant  
45 population was difficult to capture given the lack of early testing and the presence of  
46 asymptomatic infected patients<sup>1,2</sup>.

47

48 During this period of uncertainty early in the pandemic, most national and regional  
49 public health authorities and medical care professionals advocated for the enforcement  
50 of protective measures including wearing masks, quarantining at home when possible,  
51 and keeping social distancing. These non-pharmaceutical interventions or shielding  
52 measures have been shown to be highly effective in mitigating epidemic curves in the  
53 larger population especially during different “lockdown” periods in myriad countries<sup>3-6</sup>

54 but the effectiveness among pregnant patients at that time are still unknown.

55

56 Studies have shown that pregnant patients are at higher risk of getting seriously ill from  
57 SARS-CoV-2 compared to non-pregnant patients<sup>7,8</sup>. A meta-analysis showed that  
58 compared to non-pregnant patients of reproductive age with COVID-19, pregnant  
59 patients are at increased risk of severe disease from COVID-19, with increased risk of ICU  
60 admission mechanical ventilation, and death<sup>9,10</sup>. In this study we aim to model exposure  
61 rates in the pregnant vs. general populations and evaluate the efficacy of both shielding  
62 and behavior changes during pregnancy on reducing both infection exposure and its  
63 ramifications for morbidity and mortality to SARS-CoV-2 among pregnant patients. The  
64 estimation of effectiveness of shielding during pregnancy relies on the comparison of  
65 estimates of past exposure to infection between pregnant patients and the general  
66 population. Serology tests can identify past infections and enable estimation of the  
67 number of total infections. However, naturally formed immunoglobulins targeting the  
68 virus (i.e., those generated by native infection and not vaccination) have been reported  
69 to wane below the detectable level of serological assays quite rapidly (e.g., after several  
70 months)<sup>11,12</sup>. The cumulative level of exposure to SARS-CoV-2 in a population therefore is  
71 not directly measurable and has to be inferred through modeling. Here, we propose a  
72 new method to estimate the cumulative exposure of SARS-CoV-2 among pregnant  
73 patients and employ a peer-reviewed model to estimate the cumulative exposure  
74 among general population in New York City, accounting for expected levels of antibody  
75 waning (seroreversion). These results have implications on future infectious disease  
76 prevention strategies in pregnancy.

77

## 78 **Results**

### 79 **Dynamic model of SARS-CoV-2 infection**

80 The time course of SARS-CoV-2 infection among pregnant patients can be reconstructed

81 utilizing both RT-PCR and serology testing results by following the timeline of a typical  
82 SARS-CoV-2 infection. Most individuals, once infected, experience an incubation period  
83 before developing some symptoms of COVID-19 infection, while some individuals will  
84 remain asymptomatic throughout. The onset of RT-PCR positivity varies across  
85 individuals and types of clinical specimens<sup>13</sup> but systematic review studies showed that  
86 the highest percentage virus detection was from nasopharyngeal sampling between 0  
87 and 4 days post-symptom onset at 89% (95% confidence interval (CI) 83% to 93%)  
88 dropping to 54% (95% CI 47 to 61) after 10 to 14 days<sup>14</sup>. In addition to testing SARS-CoV-  
89 2 RNA load using RT-PCR testing SARS-CoV-2-specific IgM and IgG antibody (in the  
90 absence of vaccination) is another method for identifying history of infection. Although  
91 the precise timing of IgM and IgG antibody detectability depends on the testing kits and  
92 varies across different individuals<sup>15,16</sup>, on average the viral RNA is detectable one or two  
93 weeks earlier by RT-PCR than the antibody detectable by serological assays<sup>16,17</sup>.  
94 Assuming that the RT-PCR is positive before serology positivity, we divided the  
95 population of pregnant patients into five compartments: 1) RT-PCR negative and  
96 serology negative without previous exposure ( $X_{00}$ , naïve); 2) RT-PCR positive and  
97 serology negative ( $X_{10}$ , early-phase infected); 3) RT-PCR positive and serology positive  
98 ( $X_{11}$ , middle-phase infected); 4) RT-PCR negative and serology positive ( $X_{01}$ , late-phase  
99 infected), and 5) both RT-PCR and serology negative with history of previous infection  
100 ( $Z_{00}$ , past infected) (Table 1).

101

Variables	Definition
$X_{00}$	proportion of naïve population who are both RT-PCR and serology negative and never exposed
$X_{10}$	proportion of early-phase infected population who are RT-PCT positive but serology negative
$X_{11}$	proportion of middle-phase infected population who are both RT-PCR and


	serology positive
$X_{01}$	proportion of late-phase infected population who are RT-PCR negative but serology positive
$Z_{00}$	proportion of past infected population who are both RT-PCR and serology negative but previously exposed

102 *Table 1. A list of patient compartments or model variables and their definitions.*

103

104 We next defined four transmission quantities or parameters to link these above  
 105 mentioned 5 time-based compartments: force of infection,  $\lambda_\tau$ ; average time lag  
 106 between virus detectability by the RT-PCR test and antibody detectability by the serology  
 107 assay,  $1/\tau$ ; average time lag between antibody detectability by the serology assay and  
 108 virus undetectability by the RT-PCR assay,  $1/\sigma$ ; and antibody decay rate,  $\beta$  (Figure 1).

109



110

111 *Figure 1. Schematic diagram of the dynamic model structure for RT-PCR and serology status.*

112 The whole length of infectious period for pregnant patients can be therefore  
 113 approximated by the sum of time delay between virus detectability and antibody  
 114 detectability and the average time lag between antibody detectability and virus  
 115 undetectability. We developed a dynamic model to study temporal changes of both RT-  
 116 PCR and serology status in pregnant patients (Figure 1) with associated variables (Table  
 117 1) and parameters. Further details about the model can be found in the Methodology  
 118 Section.

119

## 120 **Longitudinal Cross-Sectional RT-PCR and Serology Results**

121 We modeled the exposure of 2196 pregnant patients who delivered at a New York City

122 hospital from April 20, 2020 through December 27, 2020 based on SARS-CoV-2 testing  
123 performed on discarded samples obtained from birth admission using data from  
124 quantitative real-time polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 viral  
125 infection, or serology studies assaying levels of Immunoglobulin (Ig)G and IgM as a  
126 marker of the immune response to SARS-CoV-2 infection (Demographics in Table S1,  
127 Materials and Methods). Of the 2196 patients, 2.7% were positive and 97.3% were  
128 negative for RT-PCR testing results; and 11.2% were positive and 88.8% were negative  
129 and for serology testing results. For both tests combined, 2.2% were both positive for RT-  
130 PCR and serology, 0.5% were RT-PCR positive and serology negative, 9.0% were RT-PCR  
131 negative and serology positive, and 88.3% were both RT-PCR negative and serology  
132 negative.

133

#### 134 **Fitting data from pregnant patients to the dynamic model**


135 The test results of RT-PCR and serology allow us to divide our population of pregnant  
136 patients into four data-driven categories: a) both RT-PCR negative and serology negative;  
137 b) RT-PCR positive and serology negative; c) both RT-PCR positive and serology positive;  
138 and d) RT-PCR negative and serology positive. The challenge in getting from test results  
139 to dynamic model compartments is that the first compartment ( $X_{00}$ , naïve) and the last  
140 compartment ( $Z_{00}$ , past infected) in the dynamic model (Figure 1) both manifest as both  
141 RT-PCR and serology negative, and are thus indistinguishable. To overcome this  
142 challenge, we developed a Bayesian measurement model to fit the test result data,  
143 which connects model predictions of the five time-based modeling-compartments to the  
144 measurements of the four data-driven categories.

145

146 Different models (1-4) were used to analyze different assumptions about the force  
147 infection among pregnant patients. In model 1, we assumed the force of infection is  
148 constant over time, and then relaxed the assumptions by assuming a time-varying force

149 of infection in models 2-4 (for details of how these models differ, see the parameters in  
 150 Table 2). Model fitting results showed that predictions from all four dynamic models  
 151 have good agreement with measurements from the data-driven categories each  
 152 calendar week (Figure 2).

Figure 2



153

154 *Figure 2. Time evolution measurements and fitted test-result model estimates of the SARS-CoV-2 RT-PCR and antibody*  
 155 *status among patients who gave birth between 20 April 2020 and 21 December 2020. Panel (A)-(D) respectively shows*  
 156 *the model fitting results for four data-driven categories: A) both RT-PCR negative and serology negative; B) RT-PCR*  
 157 *positive and serology negative; C) both RT-PCR positive and serology positive; and D) RT-PCR negative and serology*  
 158 *positive. In each panel, the orange solid circles and black error bars represent the measured proportion of patients*  
 159 *who were giving birth and in one of the four RT-PCR and serology categories and their credible intervals respectively.*  
 160 *The green, orange, purple and pink lines in each panel show the median of estimates from Model 1-4, for proportions*  
 161 *of patients who were giving birth in each of the four categories, while the shaded areas correspond to the 90% credible*  
 162 *intervals. The models differ in the time-dependence of the force of infection; Model 1 assumes a constant force of*  
 163 *infection while Models 2-4 assume time-varying force of infection.*

164

165

166 **Transmission parameters of COVID-19 in pregnant patients are estimated to be**  
 167 **consistent with those estimated for general population**

168 Data fitting allowed for the estimation of the transmission parameters. The posterior  
 169 estimates of parameters for pregnant patients from the four models were summarized in  
 170 Table 2. **Error! Reference source not found.** The model also estimated the proportion of  
 171 patients who were giving birth but not exposed to SARS-CoV-2 ( $y_{00}$ ) by the beginning of  
 172 our study in April 2020.

173

Parameter(unit)		Definition	Model	Median	5%	95%
$\tau^{-1}$ (days)		average time lag	1	7	4	18
		between virus	2	5	3	16
		detectability and	3	5	3	10
		antibody detectability	4	6	4	13
$\sigma^{-1}$ (days)		average time lag	1	22	14	37
		between antibody	2	18	11	32
		detectability and virus	3	17	11	27
		undetectability	4	18	12	28
$\beta^{-1}$ (days)		average time lag	1	152	84	336
		between	2	118	64	270
		seroconversion and	3	110	65	208
		seroreversion among pregnant patients	4	117	66	240
$y_{00}$ (-)		proportion of patients	1	0.87	0.79	0.90
		who were giving birth	2	0.86	0.76	0.90
		and not exposed by	3	0.86	0.74	0.89
		20 April 2020	4	0.85	0.74	0.89
$\lambda_{\tau}$	$\lambda_{11}$ (-)	force of infection	1	0.0052	0.0022	0.010



	$\lambda_{21}(-)$		2	0.0063	0.0028	0.013
	$\lambda_{22}(-)$		2	0.0079	0.0025	0.0182
	$\lambda_{31}(-)$		3	0.0041	0.0052	0.019
	$\lambda_{32}(-)$			0.011	0.0052	0.019
	$\lambda_{33}(-)$			0.0077	0.0030	0.019
	$\lambda_{41}(-)$		4	0.00013	0.000088	0.00072
	$\lambda_{42}(-)$			0.0095	0.0051	0.016
	$\lambda_{43}(-)$			0.0070	0.0013	0.0178
	$\lambda_{44}(-)$			0.0083	0.0033	0.019

174 *Table 2. Parameter estimates (associated 90% credible intervals) among pregnant patients for each model fit.*

175 We found that the estimates of the time difference between RT-PCR positivity and  
 176 serology positivity, and the duration of the infectious period for pregnant patients are  
 177 very robust, on average 5.5 days (95% Credible Interval, CrI (3.3, 16.7) days), and 18.8  
 178 days (95% CrI (11.3, 34.3) days), respectively. These estimates are largely comparable  
 179 with those for the general population<sup>13,18-22</sup>. After seroconverting, seropositivity is  
 180 estimated to be maintained for 124 days on average (95% CrI: (63, 320) days) among  
 181 exposed pregnant patients. This relatively rapid seroreversion is consistent with  
 182 estimates from the corresponding observational study, where analysis of the  
 183 relationship between the elapsed time from the date of symptom onset and the  
 184 antibody levels for pregnant patients demonstrated that the IgG positivity status could  
 185 last approximately 110 days on average with a lower bound of the 95% confidence  
 186 interval of 82 days but with an upper bound that is uncertain and possibly very large<sup>2</sup>.


187

188 **Estimated SARS-CoV-2 exposure in pregnant patients is higher than seropositivity rates**  
 189 **would suggest**

190 The estimated seroprevalence (proportion of pregnant patients who are seropositive)  
 191 from each of the dynamic models (Figure 3) match that of our data (Figure 2B-D). We

192 next estimated the exposure to SARS-CoV-2 in the pregnant patients and found that  
193 exposure is estimated to be much higher than serology positivity (Figure 3). Due to the  
194 rapid decline in antibody levels after natural infection confirmed in both experimental  
195 analyses<sup>23-25</sup> and modelling analyses<sup>11,12</sup>, there is a gap between seropositivity and the  
196 cumulative level of exposure; furthermore, this gap increases with time due to  
197 increasing exposure levels over time (Figure 3).

198




199

200 *Figure 3. Time evolution of SARS-CoV-2 exposure and seroprevalence among patients who gave birth*  
201 *between 20 April 2020 and 21 December 2020. The orange solid circles and black error bars represent the*  
202 *measured proportion of patients who were giving birth and serology positive and their credible intervals*  
203 *respectively. The green, orange, purple and pink lines show the median estimates of exposure for patients*  
204 *who were giving birth from Model 1, Model 2, Model 3 and Model 4 respectively; shaded areas correspond*  
205 *to 90% credible intervals. The light green, yellow, brown and grey lines show the median estimates of*  
206 *seroprevalence for patients who were giving birth from Model 1, Model 2, Model 3 and Model 4*  
207 *respectively; shaded areas correspond to 50% credible intervals.*

208 **SARS-CoV-2 exposure in pregnant patients at the time of birth rose from half that of**  
209 **the general population to equal that of the general population by late 2020**

210 We next compared cumulative level of exposure among pregnant patients with of the  
211 general population of New York City from the same time period. In brief, the levels of  
212 exposure in general population were estimated by applying our previously published  
213 inference methodology<sup>11</sup> to the epidemic data including mortality and seroprevalence in  
214 general population of New York City (model fitting and parameter estimation results for  
215 the general population can be found in Figure S1 and **Error! Reference source not**  
216 **found.**Table S respectively). The level of exposure in pregnant patients during April and  
217 May of 2020 is estimated to be around half of that in December 2020 in all four models  
218 (Figure 3 and 4). This means that the exposure estimates of pregnant patients  
219 approaches that of the general population by November and December of 2020 (Figure  
220 4).

221



222

223 *Figure 4. Comparisons of estimates of exposure in patients who were giving birth from four models and*  
224 *general population. The red line shows the median estimates of exposure from general population while*  
225 *the shaded areas correspond to the 95% credible interval; the green, yellow, green, blue and pink line*  
226 *shows the median estimates of exposure from Model 1, Model 2, Model 3 and Model 4 for patients who*  
227 *were giving birth respectively, while the deep and shadow shaded areas correspond to the 50% credible*  
228 *intervals.*

229

## 230 **Discussion**

231 Positive results from RT-PCR testing and serology testing can both be used to identify  
232 infected or recently infected individuals. While an infected individual turns RT-PCR  
233 positive and then RT-PCR negative within the span of days to a week, a positive serology  
234 test result can serve as a maintained marker of infection that last for months. By  
235 capturing this dynamic effect of antibody waning in our models, we found that SARS-  
236 CoV-2 exposure estimates were much higher than the seroprevalence estimates for our  
237 sample of pregnant patients and the general public in New York City. These results  
238 confirm that previous studies looking at RT-PCR positive testing rates or seroprevalence  
239 alone will substantially underestimate population-level and subgroup exposure to SARS-  
240 CoV-2.

241

242 We found that patients who gave birth between April and August of 2020 had lower  
243 levels of exposure to SARS-CoV-2 compared to the general population. In fact, in the first  
244 months of the pandemic (April and May 2020), the exposure levels of pregnant patients  
245 were half of the exposure levels of the general population in New York City, and half of  
246 the exposure levels in pregnant patients who gave birth by the end of 2020. To  
247 understand the possible variables that contribute to this lower exposure level in  
248 pregnant patients who gave birth early in 2020, we must take into account the  
249 distinctions between the experience of pregnant patients who gave birth in early 2020  
250 vs. late 2020. Patients that gave birth before August 2020—before the level of exposure  
251 in pregnant patients became comparable to that of non-pregnant patients—were all at

252 least in their mid to late first trimester by the time that the pandemic hit New York City.  
253 This means that most of these patients had a high probability of knowing about their  
254 pregnancy at the onset of the pandemic, and it is possible that this knowledge of  
255 pregnancy led to behavior changes that made them more cautious than the general  
256 population. In contrast, the patients giving birth towards the end of 2020 were not  
257 pregnant and/or did not know of their pregnancy before the onset of the pandemic and  
258 may not have behaved differently than the general population; in other words, they  
259 could be considered part of general population in early 2020. During the early part of  
260 the pandemic, the population only had access to shielding measures and other non-  
261 pharmaceutical measures for prevention of disease exposures (since vaccinations only  
262 became available for the general population in early 2021). Thus, the reduction exposure  
263 in pregnant patients by about half early in the pandemic may be attributed to  
264 effectiveness of shielding measures (Table S5). Our current data do not address whether  
265 pregnant patients (especially those that gave birth early in the pandemic) were more  
266 stringent than the general population in following recommendations for behavioral  
267 changes and other non-pharmaceutical interventions, or whether they had additional  
268 means of improving the efficacy of shielding in preventing exposure. It is less likely that  
269 biologic differences from the state of being pregnant contributed to exposure  
270 differences as the pregnant patients that gave birth later in 2020 had similar exposures  
271 to the general population.

272  
273 Such a high-level reduction of exposure might have been associated with a reduction in  
274 infection and especially a reduction of severe COVID-19 illness and, consequently, in  
275 mortality in pregnant patients. A large-scale retrospective analysis from a database that  
276 covers about 20% of the American population and includes 406 446 patients hospitalized  
277 for childbirth (6380 (1.6%) of whom had COVID-19) compared outcomes for pregnant  
278 patients with and without COVID-19 from April–November 2020<sup>26</sup>. It concluded that in-

279 hospital maternal death was rare, but rates were significantly higher for patients with  
280 COVID-19 (141/100 000 patients, 95% CI 65–268) than for patients without COVID-19  
281 (5/100 000 patients, 95% CI 3.1–7.7). The estimate of maternal death rate is consistent  
282 with the study from the UK AAP SONPM registry, where a perinatal maternal mortality  
283 rate of 167/100 000 (for patients who have COVID-19 around the time of birth) was  
284 estimated<sup>9,27</sup>. Further calculation shows that the 40% to 50% reduction on exposure to  
285 SARS-CoV-2 estimated by our study might have led to the prevention of 70 (95% CI 26–  
286 134) per 100,000 maternal deaths in New York City.

287

288 After the period included in our study, additional SARS-CoV-2 preventative measures in  
289 the form of vaccinations were introduced in 2021 although strict quarantine regulations  
290 were also lifted from the city by then. Pregnant patients were not included in studies  
291 testing the safety and efficacy of COVID-19 vaccines. Studies conducted since the start of  
292 vaccination distribution including those looking at the real-world implementation of  
293 vaccination have confirmed the safety and effectiveness of vaccines specifically for  
294 pregnant patients, their placentas, and their neonates<sup>28-32</sup>. In fact, one study showed  
295 that vaccinated pregnant patients had almost 50:1 lower odds of severe COVID-19  
296 infection<sup>32</sup>. Our data highlights the utility of shielding measures, and argues for an  
297 integrated intervention as suggested by CDC and NHS guidelines, which includes a  
298 combination of vaccination and shielding to reduce the morbidity and mortality of  
299 COVID-19 during pregnancy.

300

301 Our study has several important strengths, the two most important of which are robust  
302 data on a cohort of pregnant patients assessed over an extended period of time tested  
303 with both RT-PCR and serology throughout 2020, and the use of a novel model for  
304 reproducibly calculating disease exposure from testing data. While the lacuna in data  
305 capture in May and June could potentially influence the performance of parameter

306 inference, varying model assumptions on the force of infection (as detailed in the  
307 Materials and Methods) found the estimated parameters and level of exposure to be  
308 robust and therefore clarified the likely minimal impact caused by missing data.

309

310 While the pregnant patient population is from a single NYC institution which may not be  
311 representative of the broader population, this population allowed for uniformity in  
312 testing and the study of a large cohort of patients.

313

314 Our model was structured to recapitulate the average course of SARS-CoV-2 infection  
315 with turning RT-PCR positive occurring before becoming serology positive. However, not  
316 all disease courses follow this linear model structure. It is also possible that the state of  
317 pregnancy may alter the susceptibility to SARS-CoV-2 infection, although current  
318 evidence does not support that pregnancy increases the susceptibility of infection. In  
319 addition, the antibody decaying rate may differ during pregnancy. We should note that  
320 the thresholds of seropositive and seronegative assignment might vary between assays,  
321 and the performances of assays (including sensitivity and specificity) are different. Our  
322 study is not set up for longitudinal follow-up of our cohort, thus our data is not sufficient  
323 to evaluate the impact of pregnancy on the antibody decaying rate. While more detailed  
324 longitudinal serological data could be collected and modelled during pregnancy,  
325 incorporating antibody kinetics into transmission models may hinder the applicability of  
326 estimates resulting from different assays<sup>11</sup>.

327

328 In summary, we used a novel model to evaluate SARS-CoV-2 exposure levels in different  
329 populations using seroprevalence data and RT-PCR data, comparing exposure levels in  
330 pregnant patients in New York City to the levels in the general City population. This  
331 permits us to quantify the impact of shielding measures in preventing exposure during  
332 pregnancy across the first year of the pandemic. We estimate the impact of self-

333 protection on reducing the level of exposure among pregnant patients during early 2020  
334 who gave birth in this New York City hospital to be approximately 50%. These results,  
335 showing time-varying differences in exposure to SARS-CoV-2 in pregnant compared to  
336 non-pregnant populations, may have led to significant reduction in maternal morbidity  
337 and mortality in the early months of the pandemic. The estimated total exposure in  
338 pregnant patients and general population of New York City are both more than double  
339 the latest serology positive measurements.  
340  
341



## 342 **Materials and Methods**

### 343 **Pregnant patients data**

344 Pregnant patients giving birth at a single New York City hospital between 20 April 2020  
345 and 27 December 2020 were included in this study (Table S1). 2682 pregnant patients  
346 with clinical data capture and sample capture could have had either RT-PCR testing or  
347 serology testing or were untested (unknown). Among these 2682 patients in terms of  
348 RT-PCR, 97.7% were tested and 2.3% were unknown; in terms of serology tests, 89.9%  
349 were tested and 10.1% were unknown. For testing results breakdown: 10% were RT-PCR  
350 negative but serology unknown; 0.3% were both RT-PCR and serology unknown; 8.1%  
351 were RT-PCR negative and serology positive, 0.075% were RT-PCR unknown and serology  
352 positive, 2.1% were both RT-PCR and serology positive, 77.18% were both RT-PCR and  
353 serology negative, 2.0% RT-PCR unknown and serology negative, and 0.56% were RT-  
354 PCR positive and serology negative. After screening the distribution of unknown tests  
355 results for PCR and serology on the calendar week, 2196 pregnant patients were  
356 included in the mathematical modelling.

357

358 The serology was detected in the serum or plasma from peripheral blood collected  
359 during admission for delivery. The serology test was performed using the clinical testing  
360 Pylon 3D platform (ET HealthCare, Palo Alto, CA). The Pylon 3D platform<sup>32</sup> utilizes a  
361 fluorescence-based reporting system that allows for the semiquantitative detection of  
362 anti-SARS-CoV-2 IgG and IgM with a specificity of 98.8% and 99.4%, respectively. In this  
363 paper, we denoted the serology status of every pregnant patient as positive if either IgG  
364 or IgM was positive and as negative if both IgG and IgM were negative.

365 Pregnant patients underwent RT-PCR testing for SARS-CoV-2 using nasopharyngeal  
366 swabs.

367 The observed cross-sectional data for pregnant patients is restructured into four  
368 trajectories for model fitting: weekly proportion of RT-PCR and serology negative time-  
369 series, weekly proportion of RT-PCR positive and serology negative time-series, weekly

370 proportion of RT-PCR positive and serology positive time-series and weekly proportion  
371 of RT-PCR negative and serology positive time-series.

### 372 **General population data**

373 The seroprevalence data for general population in New York City Metro Area (including  
374 Manhattan, Bronx, Queens, Kings and Nassau) from February 2020 to December 2020  
375 and the daily total (including confirmed and probability) mortality data were extracted  
376 from US Department of Health and Human Services Centers for Disease Control and  
377 Prevention CDC Data Tracker<sup>33</sup>. Details of the seroprevalence data used here can be  
378 found elsewhere<sup>12,34</sup>.

379

### 380 **Exposure inference in pregnant patients**

381 We first develop a dynamic model diagramed in Figure 1 for the temporary changing  
382 status of RT-PCR and serology among pregnant patients based on the COVID-19 disease  
383 progression. Transmission parameters specific to pregnant patients are defined in the  
384 dynamic model (Table 2). A set of ordinary differential equations (ODEs) describing the  
385 time evolution of  $X_{00}, X_{10}, X_{11}, X_{01}$  and  $Z_{00}$  can be written as follows:

386

$$387 \quad \frac{dX_{00}(t)}{dt} = -\lambda_{\tau}(t)X_{00}$$

$$388 \quad \frac{dX_{10}(t)}{dt} = \lambda_{\tau}(t)X_{00} - \tau X_{10}$$

$$389 \quad \frac{dX_{11}(t)}{dt} = \tau X_{10} - \sigma X_{11}$$

$$390 \quad \frac{dX_{01}(t)}{dt} = \sigma X_{11} - \beta X_{01}$$

$$391 \quad \frac{dZ_{00}(t)}{dt} = \beta X_{01}$$

392

*Equation 1*

393 The initial conditions of  $X_{00}, X_{10}, X_{11}, X_{01}$  and  $Z_{00}$  at  $t = 0$  are denoted as

394  $y_{00}, x_{10}, x_{11}, x_{01}$  and  $z_{00}$ . Here,  $t = 0$  refers to 20 April 2020 (calendar week 17 in

395 2020) when the first data of pregnant patients was collected. The minimum time step in  
396 the ODEs is one week. We reparametrize the initial conditions as follows

397

$$398 \quad x_{10} = k_{10}(1 - y_{00})$$

$$399 \quad x_{11} = k_{11}(1 - y_{00} - k_{10}(1 - y_{00}))$$

$$400 \quad x_{01} = k_{01} \left( 1 - y_{00} - k_{10}(1 - y_{00}) - k_{11}(1 - y_{00} - k_{10}(1 - y_{00})) \right)$$

$$401 \quad z_{00} = 1 - x_{10} - x_{11} - x_{01}$$

402

*Equation 2*

403 where  $\{k_{10}, k_{11}, k_{01}\}$  are tool parameters and constrained between 0 and 1 so that

404  $\{x_{01}, x_{11}, x_{10}, z_{00}\}$  can be constrained between 0 and 1. This is mainly for the

405 convenience of MCMC implementation in Rstan. The posterior estimates of

406  $\{k_{10}, k_{11}, k_{01}\}$  in each model can be found in Figure S4.

407 In Equation 1,  $\{\lambda_{\tau}(t)\}$  is the force of infection. We first assume  $\lambda_{11}(t)$  is constant over

408 time ( $17 \leq t \leq 53$ ) in Model 1 and then relax it by assuming a piece-wise constant at a

409 fixed time step. To test the sensitivity, we try several different steps including 18 weeks

410 in Model 2,

$$411 \quad \begin{cases} \lambda_{21}, & 17 \leq t < 35 \\ \lambda_{22}, & 35 \leq t \leq 53 \end{cases}$$

412

*Equation 3*

413 12 weeks in Model 3,

$$414 \quad \begin{cases} \lambda_{31}, & 17 \leq t < 29 \\ \lambda_{32}, & 29 \leq t < 41 \\ \lambda_{33}, & 41 \leq t \leq 53 \end{cases}$$

415

*Equation 4*

416 and 9 weeks in Model 4,

$$417 \quad \begin{cases} \lambda_{41}, & 17 \leq t < 26 \\ \lambda_{42}, & 26 \leq t < 35 \\ \lambda_{43}, & 35 \leq t < 44 \\ \lambda_{44}, & 44 \leq t \leq 53 \end{cases}$$

418

Equation 5

419 and then compare main model results. We denote the numerical solutions of ODE

420 system defined in Equation 1 as  $\hat{X}_{00}, \hat{X}_{10}, \hat{X}_{11}, \hat{X}_{01}$  and  $\hat{Z}_{00}$ .

421

422 Following the dynamic model, we develop a Bayesian measurement model to model the

423 data observation process so that the parameter estimation and model fitting can be

424 conducted simultaneously using MCMC in Rstan<sup>35</sup>. The model with associated

425 parameters (Table S) is described as follows:

426

427  $\lambda_{ij} \sim \text{uniform}(0,1), \lambda_{ij} \in [0,1]$

428  $\sigma \sim \text{uniform}(0,1), \sigma \in [0,1]$

429  $\tau \sim \text{gamma}(4,3), \tau \in [0.5]$

430  $\beta \sim \text{uniform}(0,1), \beta \in [0,1]$

431  $y_{00} \sim \text{beta}(8,2), y_{00} \in [0,1]$

432

Equation 6

433  $(x_{00}^{obs}(t), x_{10}^{obs}(t), x_{11}^{obs}(t), x_{01}^{obs}(t))$

434  $\sim \text{Multinomial}(N(t), \hat{X}_{00}(t) + \hat{Z}_{00}(t), \hat{X}_{10}(t), \hat{X}_{11}(t), \hat{X}_{01}(t))$

435

Equation 7

436 where  $x_{00}^{obs}(t), x_{10}^{obs}(t), x_{11}^{obs}(t)$  and  $x_{01}^{obs}(t)$  are the measured numbers of pregnant

437 patients at calendar week  $t$  who were a) both RT-PCR and serology negative, b) RT-PCR

438 positive and serology negative, c) both RT-PCR and serology positive and d) RT-PCR

439 negative and serology positive respectively.  $\hat{X}_{10}(t), \hat{X}_{11}(t), \hat{X}_{01}(t)$  are ODE-predicted

440 individuals at calendar week  $t$  who were in RT-PCT positive and serology negative, RT-

441 PCT positive and serology positive, RT-PCT negative and serology positive respectively.

442  $\hat{X}_{00}(t) + \hat{Z}_{00}(t)$  is the ODE-predicted total number of pregnant patients at calendar

443 week  $t$  who were either both RT-PCT and serology negative.

444

445 We use Bayesian inference (Hamiltonian Monte Carlo algorithm) in RStan to fit the  
446 model to RT-PCR and serology data by running four chains of 20,000 iterations each  
447 (burn-in of 10,000). We use 5% and 95% percentiles from the resulting posterior  
448 distributions for 90% CrI for the parameters. The Gelman–Rubin diagnostics ( $\hat{R}$ ) given in  
449 Table S show values of 1, indicating that there is no evidence of non-convergence for  
450 either model formulation. Furthermore, the effective sample sizes ( $n_{eff}$ ) in Table S are  
451 all more than 5,000, meaning that there are many samples in the posterior that can be  
452 considered independent draws.

453

#### 454 **Exposure inference in general population**

455 For general population in New York City, we collected morality and seroprevalence time-  
456 series data as described in the Data Description section and fitted a published model  
457 under the assumption of constant infection fatality ratio<sup>11</sup>. In the meanwhile, we got the  
458 estimates of cumulative exposure over time and two parameters related to the general  
459 population of New York City: they are infection fatality ratio,  $\alpha$  and antibody decaying  
460 ratio,  $\omega$  (Table S). Through comparing the exposure level to SARS-CoV-2 among  
461 pregnant patients and general population, we estimated the effectiveness of shielding  
462 during pregnancy.

463

464 **Acknowledgments:** Y.J.Y. acknowledges funding from The Bender Foundation, Inc. and  
465 Weill Cornell Medical Center. L.J.W. received financial support from the Li Ka Shing  
466 Foundation and the University of Oxford’s COVID-19 Research Response Fund. The  
467 funders had no role in study design, data collection and analysis, decision to publish, or  
468 preparation of the manuscript.

469

470 **Ethical issues:** IRB approval was obtained from Weill Cornell Medicine for this study.

471

472 **Author contributions:**

473 L.J.W., N.H., Y.J.Y. conceived and designed the study. E.A.M, Y.J.Y, A.C.S, D.E, S.R, I.M  
474 provided patient samples and clinical information, or performed sample testing. S.C.,  
475 E.A.M and Y.J.Y. cleaned the data, S.C., A.G.P. and L.J.W. developed the methodology and  
476 conducted the formal analysis. S.C., Y.J.Y., E.A.M. and L.J.W. wrote the original  
477 manuscript. All authors reviewed and provided analytical input and approved the  
478 manuscript. Y.J.Y. and L.J.W. supervised the study.

479

480 **Competing interests:** The authors have declared that no competing interests exist.

481

482 **Data and materials availability:** All codes and materials used in the analyses can be  
483 accessed at: [https://github.com/SiyuChenOxf/COVID-19Exposure-](https://github.com/SiyuChenOxf/COVID-19Exposure-ShieldingPregnantWomen)  
484 [ShieldingPregnantWomen](https://github.com/SiyuChenOxf/COVID-19Exposure-ShieldingPregnantWomen). All parameter estimates and figures presented can be  
485 reproduced using the code provided. This work is licensed under a Creative Commons  
486 Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use,  
487 distribution, and reproduction in any medium, provided the original work is properly  
488 cited. The datasets from pregnant patients can be made available from the  
489 corresponding authors on reasonable request.

490

491 **References**

- 492 1. Prabhu, M., *et al.* Pregnancy and postpartum outcomes in a universally tested  
493 population for SARS-CoV-2 in New York City: a prospective cohort study. *BJOG: An*  
494 *International Journal of Obstetrics & Gynaecology* **127**, 1548-1556 (2020).
- 495 2. Kubiak, J.M., *et al.* Severe acute respiratory syndrome coronavirus 2 serology levels  
496 in pregnant women and their neonates. *American journal of obstetrics and*  
497 *gynecology* **225**, 73. e71-73. e77 (2021).
- 498 3. Baker, R.E., *et al.* The impact of COVID-19 nonpharmaceutical interventions on the  
499 future dynamics of endemic infections. *Proceedings of the National Academy of*  
500 *Sciences* **117**, 30547-30553 (2020).
- 501 4. Singh, S., Shaikh, M., Hauck, K. & Miraldo, M. Impacts of introducing and lifting

- 502 nonpharmaceutical interventions on COVID-19 daily growth rate and compliance  
503 in the United States. *Proceedings of the National Academy of Sciences* **118**(2021).
- 504 5. Brauner, J.M., *et al.* Inferring the effectiveness of government interventions  
505 against COVID-19. *Science* **371**, eabd9338 (2021).
- 506 6. Flaxman, S., *et al.* Estimating the effects of non-pharmaceutical interventions on  
507 COVID-19 in Europe. *Nature* **584**, 257-261 (2020).
- 508 7. CDC: COVID-19 in Pregnant and Recently Pregnant People.
- 509 8. NHS: Pregnancy and coronavirus (COVID-19).
- 510 9. Ortiz, E.I., Herrera, E. & De La Torre, A. Coronavirus (COVID 19) infection in  
511 pregnancy. *Colombia Médica* **51**(2020).
- 512 10. Qiao, J. What are the risks of COVID-19 infection in pregnant women? *The Lancet*  
513 **395**, 760-762 (2020).
- 514 11. Chen, S., Flegg, J.A., White, L.J. & Aguas, R. Levels of SARS-CoV-2 population  
515 exposure are considerably higher than suggested by seroprevalence surveys. *PLoS*  
516 *computational biology* **17**, e1009436 (2021).
- 517 12. Shioda, K., *et al.* Estimating the cumulative incidence of SARS-CoV-2 infection and  
518 the infection fatality ratio in light of waning antibodies. *Epidemiology (Cambridge,*  
519 *Mass.)* **32**, 518 (2021).
- 520 13. Wang, W., *et al.* Detection of SARS-CoV-2 in different types of clinical specimens.  
521 *Jama* **323**, 1843-1844 (2020).
- 522 14. Mallett, S., *et al.* At what times during infection is SARS-CoV-2 detectable and no  
523 longer detectable using RT-PCR-based tests? A systematic review of individual  
524 participant data. *BMC medicine* **18**, 1-17 (2020).
- 525 15. Li, K., *et al.* Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2  
526 infection and recovery from COVID-19. *Nature communications* **11**, 1-11 (2020).
- 527 16. Wei, J., *et al.* Anti-spike antibody response to natural SARS-CoV-2 infection in the  
528 general population. *Nature communications* **12**, 1-12 (2021).
- 529 17. Sethuraman, N., Jeremiah, S.S. & Ryo, A. Interpreting diagnostic tests for SARS-  
530 CoV-2. *Jama* **323**, 2249-2251 (2020).
- 531 18. Zheng, S., *et al.* Viral load dynamics and disease severity in patients infected with  
532 SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort  
533 study. *bmj* **369**(2020).
- 534 19. Wölfel, R., *et al.* Virological assessment of hospitalized patients with COVID-2019.  
535 *Nature* **581**, 465-469 (2020).
- 536 20. Guo, L., *et al.* Profiling early humoral response to diagnose novel coronavirus  
537 disease (COVID-19). *Clinical infectious diseases* **71**, 778-785 (2020).
- 538 21. Xiang, F., *et al.* Antibody detection and dynamic characteristics in patients with  
539 coronavirus disease 2019. *Clinical Infectious Diseases* **71**, 1930-1934 (2020).
- 540 22. To, K.K.-W., *et al.* Temporal profiles of viral load in posterior oropharyngeal saliva  
541 samples and serum antibody responses during infection by SARS-CoV-2: an  
542 observational cohort study. *The Lancet infectious diseases* **20**, 565-574 (2020).

- 543 23. Seow, J., *et al.* Longitudinal observation and decline of neutralizing antibody  
544 responses in the three months following SARS-CoV-2 infection in humans. *Nature*  
545 *microbiology* **5**, 1598-1607 (2020).
- 546 24. Ibarondo, F.J., *et al.* Rapid decay of anti-SARS-CoV-2 antibodies in persons with  
547 mild Covid-19. *New England Journal of Medicine* **383**, 1085-1087 (2020).
- 548 25. Long, Q.-X., *et al.* Antibody responses to SARS-CoV-2 in patients with COVID-19.  
549 *Nature medicine* **26**, 845-848 (2020).
- 550 26. Jering, K.S., *et al.* Clinical characteristics and outcomes of hospitalized women  
551 giving birth with and without COVID-19. *JAMA internal medicine* **181**, 714-717  
552 (2021).
- 553 27. Mullins, E., *et al.* Pregnancy and neonatal outcomes of COVID-19: coreporting of  
554 common outcomes from PAN-COVID and AAP-SONPM registries. *Ultrasound in*  
555 *Obstetrics & Gynecology* **57**, 573-581 (2021).
- 556 28. Smithgall, M.C., *et al.* Placental pathology in women vaccinated and unvaccinated  
557 against SARS-CoV-2. *American Journal of Obstetrics & Gynecology* (2022).
- 558 29. Yang, Y.J., *et al.* Association of gestational age at coronavirus disease 2019 (COVID-  
559 19) vaccination, history of severe acute respiratory syndrome coronavirus 2 (SARS-  
560 CoV-2) infection, and a vaccine booster dose with maternal and umbilical cord  
561 antibody levels at delivery. *Obstetrics & Gynecology* **139**, 373-380 (2022).
- 562 30. Prabhu, M., *et al.* Antibody response to coronavirus disease 2019 (COVID-19)  
563 messenger RNA vaccination in pregnant women and transplacental passage into  
564 cord blood. *Obstetrics and Gynecology* **138**, 278 (2021).
- 565 31. Shimabukuro, T.T., *et al.* Preliminary findings of mRNA Covid-19 vaccine safety in  
566 pregnant persons. *New England Journal of Medicine* (2021).
- 567 32. Vousden, N., *et al.* Severity of maternal infection and perinatal outcomes during  
568 periods in which Wildtype, Alpha and Delta SARS-CoV-2 variants were dominant:  
569 Data from the UK Obstetric Surveillance System national cohort. *BMJ Medicine*  
570 **1**(2022).
- 571 33. CDC Data Tracker.
- 572 34. Havers, F.P., *et al.* Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the  
573 United States, March 23-May 12, 2020. *JAMA internal medicine* **180**, 1576-1586  
574 (2020).
- 575 35. Stan Development Team. RStan: The R interface to Stan. 2020; Available from:  
576 <https://mc-stan.org/>.
- 577
- 578
- 579



580 **Supplementary information**

581

	Mean/Count
	n = 2618
<b>ETHNICITY</b>	
NOT HISPANIC OR LATINO OR SPANISH ORIGIN	1724 (65.9%)
HISPANIC OR LATINO OR SPANISH ORIGIN	216 (8.3%)
AFRICAN AMERICAN	1 (0%)
MULTI-RACIAL	1 (0%)
UNKNOWN	676 (25.8%)
<b>RACE</b>	
WHITE	1315 (50.2%)
ASIAN	325 (12.4%)
BLACK OR AFRICAN AMERICAN	166 (6.3%)
AMERICAN INDIAN OR ALASKA NATION	6 (0.2%)
NAT.HAWAIIAN/OTH.PACIFIC ISLAND	3 (0.1%)
ASHKENAZI JEWISH	2 (0.1%)
MULTIPLE RACES REPORTED	14 (0.5%)
OTHER COMBINATIONS NOT DESCRIBED	253 (9.7%)
UNKNOWN	80 (3.1%)
Mom Age (SD) years	34.4 (5.0)
Gestational Age at delivery (SD) weeks	38.8 (2.1)

582 *Table S1: Patient demographics*

583

Parameter category	Symbol	Definition	Prior	Units	Range
Pregnant patients	$\lambda_{\tau}$	force of infection of pregnant patients; 1 / (average time to challenge by the virus for pregnant patients)	uniform (0,1)	week <sup>-1</sup>	[0,1]
	$\tau$	1 / (average time lag between	gamma (4,3)	week <sup>-1</sup>	[0,5]

		virus detection and antibody detection)			
	$\sigma$	1 / (average time lag between middle infection and past infection)	uniform (0,1)	week <sup>-1</sup>	[0,1]
	$\beta$	antibody decaying rate in pregnant patients	uniform (0,1)	na	[0,1]
	$\gamma_{00}$	proportion of people who are never exposed yet by April 20 <sup>th</sup> , 2020	beta (8,2)	na	[0,1]
	$k_{01}$	tool parameter in the initial condition reparameterization	uniform (0,1)	na	[0,1]
	$k_{11}$	tool parameter in the initial condition reparameterization	uniform (0,1)	na	[0,1]
	$k_{10}$	tool parameter in the initial condition reparameterization	uniform (0,1)	na	[0,1]
General population	$\alpha$	infection fatality ratio for general population	uniform (0,1)	na	[0,1]
	$\omega$	antibody decaying rate in general population based on ELISA test <sup>34</sup> .	uniform (0,1)	na	[0,1]

584 *Table S2. A list of parameters, definitions and priors used in the Bayesian inference in the model of pregnant patients*  
 585 *and general population.*

586

587

Parameter(unit)	Definition	Median	2.5%	97.5%
$\alpha$ (-)	Infection fatality ratio among general population	0.0077	0.0067	0.0087
$\omega^{-1}$ (days)	1/antibody decaying rate among general population	209	152	333

588 *Table S3. Posterior estimates of parameters in general population.*

589

Parameter	Model	$n_{eff}$	$\hat{R}$	Parameter	Model	$n_{eff}$	$\hat{R}$
$\tau$	1	9902	1	$k_{10}$	1	9954	1
	2	7876	1		2	8854	1
	3	9516	1		3	11699	1
	4	8251	1		4	8544	1
$\sigma$	1	10448	1	$k_{11}$	1	13671	1
	2	8744	1		2	13344	1
	3	11928	1		3	13863	1
	4	8241	1		4	10818	1
$\beta$	1	9982	1	$\lambda_{11}$	1	10128	1
	2	8005	1	$\lambda_{21}$	2	9273	1
	3	9154	1	$\lambda_{22}$		8502	1
	4	7953	1	$\lambda_{31}$	3	10948	1
$\gamma_{00}$	1	9330	1	$\lambda_{32}$		9698	1
	2	10350	1	$\lambda_{33}$		9549	1
	3	8152	1	$\lambda_{41}$		12655	1
	4	5675	1	$\lambda_{42}$	7391	1	
$k_{01}$	1	19436	1	$\lambda_{43}$	4	7333	1
	2	19826	1	$\lambda_{44}$		7116	1
	3	19595	1				
	4	17016	1				

590 Table S4. The effective sample size ( $n_{eff}$ ) and the Gelman—Rubin ( $\hat{R}$ ) diagnostic for the four models.


591

Model	Estimation of effectiveness of shielding (95% CrI)
Model 1	53.4% (23.5%, 72.1%)
Model 2	52.0% (16.4%, 71.1%)
Model 3	48.4% (11.4%, 67.8%)
Model 4	47.3% (6.1%, 67.5%)

592 Table S5. Estimation of effectiveness of shielding from the four models.

593

Supplementary Figure 1



594

595 *Figure S1. Time course of the SARS-CoV-2 infection among general from January 1<sup>st</sup>, 2020 to December*  
596 *31st, 2020. The orange solid circles and black error bars represent the measured seroprevalence and their*  
597 *credible intervals respectively. The blue and orange lines show the median of predictions of seroprevalence*  
598 *and exposure among general population in New York City, while the shaded areas correspond to the 95%*  
599 *credible intervals.*


600

601 We conducted a sensitivity analysis around the choice of prior of the initial conditional  
602 of proportion of pregnant patients who were not exposed previously by 20 April 2020  
603 (numerically equals to 1 minus the level of exposure in pregnant patients by 20 April  
604 2020). The results showed that the median and 50% credible band of posterior  
605 estimates are very robust (Figure S2) although a heavy left tail in the 90% and 95%  
606 credible band (Figure S3) are estimated when the priors are very weak, for example  
607 uniform (0,1). However, considering the transmission speed and antibody decaying rate

608 it is reasonable to choose a relative formative prior, such as beta (2,1) and beta (8,2)

609 and then the posterior estimates are more concentrated around 0.85.

610




611

612 *Figure S2. Comparisons of posteriors with different significant levels (50%, 90% and 95%) for the proportion of pregnant*

613 *patients who were not exposed previously by 20 April 2020 (numerically equals to 1 minus the level of exposure in*

614 *pregnant patients by 20 April 2020).*


Supplementary Figure 3



615

616 *Figure S3. Comparisons of priors and posteriors for the proportion of pregnant patients who were not exposed previously*  
617 *by 20 April 2020 (numerically equals to 1 minus the level of exposure in pregnant patients by 20 April 2020).*

618



619

620 *Figure S4. Comparison of estimates of 'instrumental parameters' among the four models.*

621